Key result
Favipiravir inhibits viral replication by targeting RNA-dependent RNA polymerase to potentially treat SARS-CoV-2.
Why the study?
What is the mechanism of action of favipiravir against SARS-CoV-2?
What is the mechanism of action of favipiravir against SARS-CoV-2?
Favipiravir inhibits SARS-CoV-2 viral replication by targeting the RNA-dependent RNA polymerase.
Favipiravir may aid SARS-CoV-2 recovery; leaves open efficacy and role pending randomized trials.
Favipiravir is a novel broad-spectrum antiviral drug against RNA viruses that has been approved for the treatment of seasonal and pandemic influenza. The use of favipiravir is a potential therapeutic approach to SARS-CoV-2 infection; several clinical trials have shown that favipiravir could effectively improve the clinical recovery and/or viral RNA clearance of patients, with proven safety profiles.1,2 Favipiravir is a prodrug and its active form, favipiravir ribofuranosyl-triphosphate (FTP), inhibits viral replication by targeting the RNA-dependent RNA polymerase (RdRp).
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2021) conducted a review in SARS-CoV-2 infection. Favipiravir was evaluated. Favipiravir is a prodrug whose active form inhibits viral replication by targeting RNA-dependent RNA polymerase, offering a potential therapeutic approach to SARS-CoV-2 infection.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: